Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial

類似資料

• Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
  著者:: Armstrong, M, 等
  出版事項: (2015)
• Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis
  著者:: Armstrong, M, 等
  出版事項: (2013)
• Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
  著者:: Armstrong, M, 等
  出版事項: (2013)
• Orlistat for overweight subjects with nonalcoholic steatohepatitis.
  著者:: Dowman, J, 等
  出版事項: (2009)
• Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis
  著者:: Armstrong, M, 等
  出版事項: (2014)